ABSTRACT Although unstable angina can be initially controlled with medical therapy in most patients, there is a high incidence of subsequent death, myocardial infarction, or need for coronary bypass surgery to control symptoms. Identification at the time of presentation of the patient likely to do poorly on continued medical therapy would be useful in advising consideration of surgical therapy. Since coronary arterial spasm may have a significant role in the pathophysiology of unstable angina in some patients, the recently developed calcium channel antagonists may therefore be of particular benefit in the medical therapy of unstable angina. One hundred thirty-eight patients were entered into a randomized double-blind study of the efficacy of adding nifedipine to conventional treatment of unstable angina (nitrates and /3-blockers) and were followed for 18 months. Of these patients, 104 underwent coronary arteriography. A multivariate Cox's hazard function analysis was applied to variables selected from the history, electrocardiographic (ECG) changes during chest pain, and from scintigraphic and coronary arteriographic data to determine those variables most predictive of response to medical therapy. The percentage of the left ventricular myocardium supplied by vessels with 70% or greater luminal stenosis was the most significant variable in influencing failure of medical therapy defined as sudden death, myocardial infarction, or need for bypass surgery. Whether or not the patient received nifedipine was the second most powerful variable, with the use of nifedipine reducing by half the relative risk of failing medical therapy. These were followed by cigarette smoking and presence of global ST segment changes during ischemia. After 18 months the nifedipine group had fewer patients failing medical therapy (p = .02), with fewer patients undergoing coronary bypass surgery (p < .01). However, nifedipine did not appear to have a preventive effect against myocardial infarction or death. Kaplan-Meier actuarial curves confirmed that medical therapy was significantly less successful in the presence of increasing numbers of significantly stenotic vessels (p = .03). However, nifedipine provided a significant beneficial effect in patients with two or more stenotic vessels (p < .01) and in whom 50% or more of the myocardium was supplied by vessels with 70% or greater stenosis (p = .01). Thus, although patients with advanced obstructive coronary disease have the greatest likelihood of unfavorable outcomes, the addition of nifedipine is of significant benefit. This group can be identified at the time of presentation by diffuse ECG changes accompanying angina and by data obtained from coronary angiography.
tients with unstable angina pectoris,'0 which enrolled 138 patients in a prospective study of the efficacy of adding the calcium antagonist nifedipine to nitrates and /3-blockers. A group of 104 patients underwent cardiac catheterization. Analysis of these patients over a follow-up period of 18 months offered the opportunity to answer important questions relating to the identification of clinical and angiographic variables predictive of successful long-term medical therapy of patients with unstable angina by means of multivariate discriminant function analysis of several risk factors and clinical and angiographic variables.
Methods
Study population. Details of the study population, including entrance and exclusion criteria, have been previously reported. 10 In brief, 138 patients with a diagnosis of unstable angina, characterized by rest angina accompanied by electrocardiographic changes, were enrolled. Patients were excluded if the episode of chest pain represented a myocardial infarction, if they were hypotensive with a systolic blood pressure of less than 90 mm Hg. or if the PR interval exceeded 0.24 sec unless they had an implanted pacemaker. Patients with a history of coronary artery bypass surgery, valvular or congenital cardiac abnormalities, or symptomatic cerebrovascular disease were also excluded.
All patients were treated with propranolol and nitrates unless a contraindication existed. There was no difference between the two groups (nifedipine vs placebo) with respect to a number of important characteristics at entry into the study (table l) .
Clinical and noninvasive evaluation. A detailed clinical, family, and social history was obtained from each patient. The ejection fraction was determined on study entry in all patients, either by gated blood pool scan or left ventriculography. Elec- trocardiograms were recorded in the presence and absence of chest pain.
Coronary arteriography. Patients were offered cardiac catheterization according to the usual practices of the attending cardiologist; 104 of the 138 patients entered into the study underwent cardiac catheterization. The remainder of the patients were not studied because of age or refusal. Patients who did not receive cardiac catheterization had a mean age of 68 ± 1 1 years compared with 58 ± 10 years for patients receiving catheterization (p = .001). There was no difference between the groups in mean duration of angina on study entry or in doses of :3-blockers and nitrates used at entry. Cardiac catheterization, including coronary angiography and left ventriculography in right anterior and left anterior oblique projections, was performed by either the percutaneous femoral or brachial technique.
Left ventriculograms and coronary angiograms were read by one author (J. A. B.), experienced in coronary angiography, who had no prior knowledge of the patient's treatment assignment nor of the patient's clinical course. Each patient was considered to have at least three major coronary arteries: left anterior descending, left circumflex, and right. The left main coronary artery was also evaluated. Patients with a large left main diagonal artery were considered to have four major arteries. The percent obstruction of the lumen diameter provided by each lesion in each vessel was assessed in several views. A lesion producing 70% or greater luminal obstruction was considered to represent significant fixed disease except in the left main coronary artery, where a 50% or greater stenosis was AData expressed as mean ± SD. BData expressed as number of subjects. considered significant. Each patient was classified as having coronary disease affecting zero, one, two, three, or more than three vessels, and the percentage of the left ventricular myocardium supplied by all vessels with 70% or more obstruction was calculated for each patient. The amount of left ventricular myocardium supplied by a given vessel or branch was estimated by considering the size and distribution of the native vessel or branches in comparison with remaining vessels. The area of the left ventricle supplied by any given vessel was expressed as a percentage of the total left ventricle. Typically the right coronary artery would supply 20% to 30%, the circumflex 20% to 25%, and the left anterior descending 45% to 60Yo of the left ventricular wall. An independent repeat reading of a random sample of the coronary angiograms resulted in less than 10% discrepancy in determinations of the degree of vessel obstruction and estimation of the percentage of left ventricular myocardium supplied by the stenotic vessels. These two variables were chosen as likely to represent the extent of obstructive coronary disease that would influence a patient's prognosis. All cardiac catheterizations were performed without complications. Drug administration. To standardize conventional medical therapy, all patients received propranolol at a minimum dose of 40 mg and long-acting nitrates (at a minimum dose of 2.5 cm of a topical preparation or 10 mg of the oral drug) every 6 hr unless contraindications existed. These drugs were continued throughout the study period. After informed consent was obtained, each patient was randomly assigned in a double-blind fashion to receive either nifedipine or placebo. Only the study statistician CIRCULATION knew the patient assignments. One capsule of the study drug (either placebo or nifedipine 10 mg) was administered every 6 hr for four doses. If no adverse effects occurred, the dose was increased to two capsules every 6 hr. The study drug, either placebo or nifedipine 20 mg every 6 hr, was continued until an outcome was reached or for a follow-up period of was used to derive the 1, 6, 12, and 18 month probabilities of successful medical therapy. The relative risks of the possible combinations of the variables predictive of failing medical therapy at 18 month follow-up were also derived. These time points were arbitrary and reasonable choices used to display the data in an easily understandable way. The analysis was performed considering all 104 patients who underwent cardiac catheterization and those patients without left main coronary stenosis. The decision to perform the analysis in this manner was made before initiation of the study.
Univariate analysis of the effect of early treatment response on overall failure was performed for the group receiving nifedipine.
Results
Results were obtained from the 104 patients who underwent cardiac catheterization. The clinical characteristics of the patients in the two study groups were similar, as shown in table 1. Coronary arteriography. There were 53 patients in the nifedipine group and 51 in the placebo group. The distribution of fixed disease was similar in the two groups ( 
160 320 480 640 DAYS FIGURE 1. Effect of drug assignment on the cumulative probability of successfully remaining on medical therapy in all patients. Nifedipine showed a significant benefit (p = .02).
nitroglycerin paste and 129 ± 77 mg/day of oral nitrates. The lower incidence of medical failure in the nifedipine group therefore cannot be attributed to a difference in standard medical therapy.
Univariate analysis in the nifedipine group showed that response to therapy within the first 5 days of treatment predicted a successful response to medical treatment over the following 18 months (p < .02). Thus patients that do well early after institution of combined nitrate, /3-blocker, and nifedipine therapy generally do better over the long term.
The Kaplan-Meier curve depicting any failure of medical therapy in all patients as the outcome is presented in figure 1 . There was a significant difference between the two groups (p = .02). This was also found when patients with left main coronary stenosis were excluded from the analysis. In addition, significantly fewer patients assigned to nifedipine treatment required coronary bypass surgery, particularly when patients with left main coronary artery disease were excluded (p < .01; figure 2 ). There was no difference in the incidence of, or time until, death or infarction in either group ( figure 3) . Thus, although the number of patients reaching this end point was small, nifedipine did not appear to have a preventive effect against death or infarction. The majority of end points reached were provided by the surgical outcome. Thus nifedipine improved the quality of life so that significantly more patients in the nifedipine group successfully continued on medical therapy.
Review of the curves shows that the majority of end of these studies. The population in this study differs from those in that it represents the broad spectrum of patients presenting with unstable angina. The distribution of anatomic disease among the study patients (table 3) is similar to that reported in other studies.14' 19- 21 The study confirms that the probability of successful medical therapy in patients with unstable angina is significantly related to the severity of coronary disease as determined by the number of significantly obstructed vessels or by the amount of left ventricular myocardium supplied by significantly obstructed vessels. This derived variable was believed to be biologically significant in determining success of medical therapy because it includes the amount of myocardium already infarcted or at greatest risk of ischemia or infarction. This proved to be correct as indicated by the multivariate analysis. A myocardial jeopardy variable was defined in the CASS registry22 in terms of whether there were severely diseased coronary vessels leading to viable anterior or inferobasal segments or both. This variable proved to be significantly related to the percentage of patients undergoing surgery. In this study, the end point of failure of medical therapy included coronary bypass surgery, but this decision was not based on anatomic considerations other than left main disease. Although a benefit was obtained by the addition of nifedipine to therapy with nitrates and /3-blockers, 15% of patients in the nifedipine group suffered infarction or sudden death and 36% required coronary revascularization. The decision for surgery was based on symptoms and not on arteriographic data other than left main disease. The study code was not broken before or after bypass surgery. It was not therefore surprising that bypass surgery for continued angina comprised the majority of end points reached.
One might have expected coronary spasm to play a major role in zero-or single-vessel disease and less of a role in patients with significant atherosclerotic disease. Although a trend was seen to suggest a benefit from nifedipine in patients with zero-or single-vessel disease, this did not reach statistical significance. This is probably because of the small number of patients in these groups. However, Kaplan- benefit was derived from the addition of nifedipine to ,3-blocker and nitrate therapy in patients with advanced fixed atherosclerotic disease. This may have been the result of its unique action as a calcium antagonist with inhibition of coronary spasm. 23 The study was performed before the availability of the results of the study by Lewis et al.24 of aspirin in men with unstable angina and only four patients in either group received aspirin or nonsteroidal anti-inflammatory agents. Only eight patients were on full-dose heparin on entry into the study. The use of subcutaneous low-dose heparin in the coronary care unit did not influence outcome as might be expected, considering that this was discontinued at time of hospital discharge. These findings are unlike those of Telford and Wilson.25 In an earlier published report of the 4 month followup of this group of patients,'0 the addition of nifedipine was shown to be of benefit for successful continuation of medical therapy over this relatively short follow-up period. Of major interest is the finding that the KaplanMeier curves became flat, with few end points occurring after 3 months of follow-up, which is similarly reflected in the probabilities of failing medical therapy (table 6 ). This suggests that the syndrome of unstable angina may be a transient phenomenon, which, if successfully managed, allows return of patients to their previous pattern of stable exertional angina. Waters et al. 26 reported on 169 patients with variant angina and also noted that the risk of infarction or death decreased markedly after 3 months, suggesting that coronary spasm may be a transient phenomenon. These findings therefore indirectly support coronary spasm as one trigger for unstable angina.
Multivariate Cox's hazard function analysis allowed identification of variables predictive of failure of medical therapy. The most important variable proved to be the percentage of left ventricular myocardium at risk of ischemia evidenced by significant obstructive coronary disease in the supplying vessels. A history of cigarette smoking exerted a detrimental influence on success of medical therapy. Although the study does not evaluate the effect of discontinuing smoking, this finding suggests that manipulation of this risk factor may improve the patient's prognosis. Global electrocardiographic changes during episodes of angina also proved to be predictive of failure of medical therapy, probably because it reflects extensive coronary disease. 27 The addition of nifedipine to the medical therapy of unstable angina was the second most powerful variable influencing success of medical therapy, with the addition of nifedipine reducing by half the relative risk of failing medical therapy within 18 months follow-up.
Although there is evidence that,/3-blockers exacerbate the duration of ischemia in patients with pure coronary vasospasm,28 in patients with fixed atherosclerotic coronary disease, /3-blockers may have a beneficial effect by reducing myocardial work. Addition of calcium channel blockers may provide benefit in some patients by opposing the potential vasoconstrictor effect of /l-blockers. As can be seen from tables 6 and 7, if the probability of failing medical therapy is extremely high, addition of nifedipine will improve the likelihood for successful medical therapy but the failure rate will remain high. In such patients consideration should be given for more aggressive therapy, including bypass surgery.
The study also demonstrated that patients that respond early to medical therapy continued to be significantly more successfully managed by medical therapy than were nonresponders. The knowledge of whether patients will or will not respond to intensive medical therapy is not available at time of presentation, but once therapy is instigated the likelihood of successful continued medical therapy can be predicted.
An important use of these data is therefore the identification of groups of patients presenting with unstable angina who would benefit from aggressive evaluation and therapy. Cardiac catheterization, which can be safely performed in these patients, will provide important prognostic information and should be considered once the patient has been stabilized medically. This study shows that nifedipine is of significant benefit when used in addition to nitrates and /3-blockers, reducing by half the risk of failure of medical therapy, even in patients with advanced obstructive atherosclerotic coronary disease. 
